Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Background Immune checkpoint inhibitors are the standard of care for first-line treatment of
patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose …

Highlights•This special article provides key recommendations on the immunotherapy
treatments of renal cell carcinoma.•Recommendations are based on available scientific data …

PURPOSE To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II
trial in patients with non–clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS …

Background Immunotherapy-based combinations including pembrolizumab plus lenvatinib
are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these …

PURPOSE COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid
tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) …

Methods Patients with previously untreated advanced/metastatic nccRCC, Karnofsky
performance status≥ 70%, and any International Metastatic Renal Cell Carcinoma …

Abstract Savolitinib (Orpathys®; HUTCHMED, AstraZeneca) is a receptor tyrosine kinase
mesenchymal epithelial transition factor (MET) inhibitor being developed for the treatment of …